Newark, DE, United States of America

Chris Allan Veale


Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 147(Granted Patents)


Location History:

  • Newark, DE (US) (1993 - 2000)
  • Newark County, DE (US) (1997 - 2000)

Company Filing History:


Years Active: 1993-2000

Loading Chart...
18 patents (USPTO):Explore Patents

Title: **The Innovations of Chris Allan Veale: Pioneering Research in Proline Derivatives**

Introduction

Chris Allan Veale, based in Newark, DE, is an accomplished inventor with a portfolio that boasts 18 patents. His work primarily focuses on the development of pharmaceutical compositions aimed at inhibiting human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE). His inventive contributions are significant in the fields of pharmacological and diagnostic studies.

Latest Patents

Among his latest inventions, Chris has developed novel proline derivatives. These compounds feature a unique structure: 1-substituted-N-[2-methyl-1-(trifluoroacetyl)propyl]pyrrolidine-2-carboxamide. The primary purpose of these derivatives is to act as inhibitors of human leukocyte elastase, which plays a critical role in various diseases affecting mammals. The inventions include formulations for pharmaceutical compositions, methods for preparing these compounds, and intermediates that are useful in their synthesis.

Career Highlights

Chris Allan Veale's career includes significant tenure at renowned companies such as Zeneca Limited and Imperial Chemical Industries Limited. His experiences have provided him a solid foundation in drug development and innovation, enabling him to contribute impactful inventions that address critical health challenges.

Collaborations

Throughout his professional journey, Chris has collaborated with notable colleagues, including Peter R. Bernstein and Elwyn Peter Davies. These partnerships reflect a continuous commitment to research and innovation, fostering an environment that promotes the advancement of science and technology.

Conclusion

Chris Allan Veale exemplifies the spirit of innovation in the pharmaceutical industry. Through his extensive research and development of proline derivatives, he has made strides in the understanding and treatment of diseases related to human leukocyte elastase. His contributions will undoubtedly continue to influence the fields of pharmacology and diagnostics for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…